Samsung Pharmaceutical Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Samsung Pharmaceutical Co Ltd with three other
companies in this sector in South Korea:
Aprogen Pharmaceuticals Inc
sales of 45.40 billion Korean Won [US$38.13 million]
of which 1%
Ildong Holdings Co Ltd
(47.05 billion Korean Won [US$39.52 million]
of which 30%
was Holdings), and
Jin Yang Pharmaceuticals Co Ltd
(46.86 billion Korean Won [US$39.36 million]
During the year ended December of 2018, sales at
Samsung Pharmaceutical Co Ltd were 46.48 billion Korean Won (US$39.05 million).
increase of 10.9%
versus 2017, when the company's sales were 41.92 billion Korean Won.
Despite this increase, sales are still
below the level achieved in 2016, when Samsung Pharmaceutical Co Ltd
reported sales of 48.22 billion Korean Won.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Samsung Pharmaceutical Co Ltd had sales
of 46.92 billion Korean Won.
Sales of Health Food Segment saw an increase
that was more than double the company's growth rate: sales were up
22.7% in 2018, from
3.03 billion Korean Won to 3.72 billion Korean Won.